also showed a trend towards a lower left ventricular dilatation and a reduced fibrosis in the scaffold group in comparison to direct injection group (n=10). These findings demonstrate that using a porous biodegradable scaffold is a promising method to improve cell delivery and engraftment into damaged myocardium.
INTRODUCTION
Ischemic injury induces a heart failure as the end of pathological remodelling of the myocardium. Conventional treatments do not replace lost cardiomyocytes, opening the way to new approaches such as genes, growth factors, and cell-based therapies. 1 Cardiac cell therapy has evolved quickly and a variety of candidate cells, mainly skeletal myoblasts, hematopoietic and more recently mesenchymal stem cells (MSCs) have been tested to repair damaged hearts. MSCs are an attractive cell source for therapeutic applications, particularly as they can be easily cultured and release a large array of soluble growths factors and cytokines underlying some paracrine effects. 2 Despite promising experimental studies and early clinical trials, up to now, progress in cell therapy is hampered by suboptimal engraftment of donor cells into the myocardium. 3 Typical approaches to deliver MSCs to infarcted myocardium are intravenous (IV), intracoronary (IC) and endocardial (EC) injection. 4 In a quantitative study evaluating these three methods for MSC delivery in a porcine delivery, Freyman et al. reported an increased, but still limited, engraftment of MSCs after IC or EC injection when compared with IV infusion (3%, 6% and 0 %, respectively). 4 EC injection offers direct localization of cells to the injured area, but engraftment is limited by leakage out of the injection sites. IC delivery was associated with a high incidence of decreased coronary blood flow. More recently, in a canine acute myocardial ischemia model, Perin et al. found an increased vascularity and greater functional improvement with EC delivery than IC delivery of MSCs. 5 The approach to improve exogenous cell delivery to tissue, whatever the cell source, is of major clinical importance and has stimulated further investigation on the use of bioengineered scaffolds as cell delivery vehicles. 6 One of the challenges involves the development of optimized biocompatible materials functioning as synthetic analogs of the extracellular matrix, that would both provide a substrate for transplanted cells and promote cell engraftment. 7 Many materials have been used including polyglycolic acid (PGA), collagen gel, alginate and gelatin mesh. In this context, we previously described the preparation of a polysaccharide-based scaffold as a novel biomaterial for cardiovascular engineering. 8 Naturally-derived polysaccharides are hydrophilic, biodegradable, biocompatible and can form highly hydrated gels that could mimick the extracellular matrix. 9 4
Naturally-derived polysaccharides are hydrophilic, biodegradable, biocompatible and can form highly hydrated gels that could mimick the extracellular matrix. 9 In the present study, we used a rat model of acute myocardial infarct to examine MSCs engraftment in infarcted tissue using this polysaccharide-based porous scaffold in comparison with endocardial injection. Syngeneic MSCs stably transduced with a lentiviral vector allowed accurate in vivo assessment of cell retention after cardiac delivery. The effects on cardiac remodelling and function were then evaluated.
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MATERIAL AND METHODS
Culture, characterization and preparation of MSCs
MSCs were obtained from the bone marrow of syngeneic adult Lewis rats (Janvier). Briefly, cells were collected by flushing femurs and expanded in DMEM (Gibco) supplemented with 1%
penicillin/streptomycin and 10% fetal bovine serum at 37°C in a 5% CO2 atmosphere. Cells were subcultured every 4-7 days.
Characterization of rat MSCs was performed by flow cytometry analysis with a phycoerythrin (PE)-conjugated anti-human CD45 (Immunotech) antibody (MoAb) (BioLegend) and with fluorescein isothiocyanate (FITC)-conjugated anti-CD90 (Becton Dickinson), anti-CD106 monoclonal and anti-CD29 MoAbs (BioLegend). MSCs were also characterized by their capacity to differentiate along adipogenic, chondrogenic, and osteogenic lineages. 10 The ability of MSCS to differentiate towards cardiac lineage is controversial. We did not obtain any cardiac differentiation from rat MSCs during our in vitro culture.
Scaffold preparation
Polysaccharide-based scaffolds were prepared using a mixture of pullulan (Hayashibara) and dextran (Pharmacia), and sodium carbonate was added as a porogen agent. 11 Chemical cross-linking was carried out using trisodium trimetaphosphate STMP (Sigma) under alkaline conditions as described. 12 After a freeze-drying step, a circular punch was used to cut 6mm diameter and 1mm thickness round-shaped porous scaffolds. GFP+ cell quantification in cardiac tissue was performed using molecular analysis of gene expression by quantitative PCR. The heart was removed and infarct region, border zone and large area of peri-infarct healthy myocardium were cut into slices <0.5mm thick and immediately submerged in RNA later stabilization reagent (Sigma, France). A reference curve was established on the basis of the GFP expression level from defined numbers of GFP+ cells (triplicate samples from 10x103 to 1x106 GFP+ cells per sample) used as calibrator. Quantitative PCR was performed on a 7500 Real Time PCR System (Applied Biosystems) with standard cycling conditions. GFP expression levels were normalized relative to the expression of rat HPRT, UBC and Ywhaz. The number of residual GFP+ cells after EC injection or scaffold administration was estimated by report to the reference curve.
Histology, immunofluorescence and immunohistochemistry analysis
Analysis were performed after administration of GFP + MSCs or MSCs double labelled with thymidine analog 5-bromo-2'-deoxyuridine BrdU (10µM for 24 hours) and with a fluorescent dye (PKH26, Sigma) (n=3, each condition). 
Molecular analysis of gene expression by quantitative reverse transcription polymerase chain reaction (RT-PCR)
MMP-2, MMP-9 and VEGF expression were measured on infarcted heart administered with MSCs using scaffold or EC injection, 1 and 2 months after infarct, in comparison with control animals submitted to infarct without cell administration. Immediately after sacrifice, samples were fixed in RNA stabilization reagent (RNA Later, Sigma). All primers were designed using intron-flanking method. Quantitative PCR was performed on a 7500 Real Time PCR System (Applied Biosystems) with standard cycling conditions. For housekeeping gene selection, the stability of various reference genes was investigated from different samples of rat infarcted hearts. The expression stability of 7 commonly used reference housekeeping genes (GAPDH, 18S, ActB, CycA HPRT, UBCand YWHAZ) was analyzed using geNorm and expression stability was determined by the Genorm program. HPRT, UBC and YWHAZ were identified as most stable genes. Then, gene expression levels were normalized relatively to the expression of rat HPRT, UBC and Ywhaz. Quantification was done with the Pfaffl's method. 13 Relative expression ratios were calculated by reporting values to those of the control animals.
Echocardiographic and catheterization protocols
For determination of cardiac function related to MSC delivery, non transduced MSCs were used. Animals were randomly assigned to the delivery method, either control, scaffold or EC group.
All cardiac echocardiograms were recorded using an Acuson 128XP (Acuson corporation, Mountain
View, California, USA) utilizing a 7-10Mhz transducer. The heart was first imaged in twodimensional mode in the parasternal long axis and short axis views, to position the M mode cursor perpendicular to the interventricular septum and left ventricular posterior wall. Then, M mode images were obtained at a 100 mm/sec speed. At least 3 measurements of LV end-diastolic (LVEDD) and end-systolic diameters (LVESD) were selected and averaged from each animal and the analysis of contractile function was derived from the LV fractional shortening fraction (LVFS): (LVEDD-LVESD/LVEDD x 100). The echocardiographic examination was performed 7 days and 2 months after myocardial infarction by a blinded observer.
Statistics
All parameters were expressed as mean values ± standard deviation, except for engraftment results expressed as median values. A t-test was performed on fibrosis and mRNA data, a one way ANOVA test was performed on echocardiographic data and a two-way ANOVA was performed on engraftment data. Statistical significance level was set at 0.05.
RESULTS
Cellularized scaffold for implantation
We first examined the optimal conditions of MSCs seeding on the scaffold. Scaffolds from 2 mm to 50 mm in diameter could easily be obtained and a 6 mm diameter porous scaffold, suitable for the size of rat hearts, was chosen (Fig. 1A) . Porosity of scaffolds was observed with Environmental Scanning Electron Microscopy (Fig. 1B) . The use of FITC-labelled dextran into polysaccharide scaffolds allowed confocal laser scanning microscopy observation of the inner structure of hydrated scaffolds. A typical single optical slice of a porous scaffold is shown on Fig. 1C .
A mean pore size of 195 µm and a porosity of 41% were calculated. Cells infiltrated very quickly (<1min) within the scaffold porous structure like in a sponge, and the maximum volume contained was 15 µL. Using a metabolic MTT assay at day 1, we confirmed that 2x10 4 to 10 6 cells/scaffold could be seeded into 6 mm porous scaffold. Absorbance data as a function of the initial cell number is shown on Fig. 1D . Cells within the transparent scaffold could be observed with light microscopy as cell clusters (Fig. 1E) . Cell viability at day 1 was demonstrated with a live & dead assay (Fig. 1F) .
A first series of experiments was conducted with FITC-labelled non-cellularized scaffolds to determine the in vivo fate of porous scaffold in rat cardiac tissue (n=2). One month after implantation, scaffold was found intact on normal cardiac tissue ( Fig. 2A , scaffold stained with alcian blue dye for imaging purposes), as confirmed by fluorescent microscopic observation of heart sections showing cardiac tissue green autofluorescence and FITC-labelled scaffold (Fig. 2B) . In contrast, the scaffold on infarcted cardiac tissue was progressively degraded after implantation and only some remnants of the FITC-scaffold were seen embedded or integrated into the adjacent tissue on infarcted heart sections at 1 month (Fig. 2 C, D) .
Engraftment of MSC
Typical MSCs were obtained and characterized by their spindle shaped morphology (Fig. 3A) and a CD45 (Fig. 3C ).
Quantification of cell engraftment into the infarcted heart was performed using MSCs transduced with a lentiviral vector that expresses eGFP (Fig. 3D) (Fig. 3E) . One month after administration of 1x10 6 eGFP + MSCs, the median number of eGFP + cells in the myocardium was greater after administration using scaffold than following EC injection with respectively 9.7% and 5.1% of the administered cells in the myocardium (Table 1) . Engraftment was confirmed at 2 months. The median number of eGFP + cells in the scaffold group and EC group represented 16% and 6.1% of the initial administered cells, respectively (n=5).
MSC localization
We then examined the ability of MSCs to migrate from the scaffold to the targeted tissue.
MSCs localization was examined using eGFP + cells or cells double-labelled with a fluorescent dye PKH26 and BrdU (n=3). When cellularized scaffolds were implemented on healthy myocardium, no labelled cells were detected in cardiac tissue. On the contrary, one month after implantation of cellularized scaffold on injured myocardium (Fig. 4A) , immunofluorescence staining detected numerous PKH-labelled cells in the thin peri-infarcted cardiac tissue (Fig. 4B) ; some BrdU-positive
MSCs were also observed in the same border area (Fig. 4C) . This suggested the influence of attractive signals from infarcted area to induce cells moving from the implanted scaffold towards the targeted area (Fig. 4D) . These data were confirmed using eGFP + cells. In animals having MSCs implemented on scaffold, clusters of GFP + cells were clearly detected in the peri-infarct area and in bordering healthy myocardium, one month (n=3) and two months (n=3) post infarct ( 
Ventricular remodelling and biochemical modifications after MSC delivery using scaffold or EC injection
It is believed that MSCs sustain the heart repair predominantly by facilitating endogenous processes, through paracrine effect particularly on scar formation and neovascularization.
Haematoxylin and eosin (Fig. 5A , top row) and sirius red (Fig. 5A , bottom row) staining in histological heart sections were examined in animals having received cellularized scaffold or EC injection. Sirius red staining indicated collagen production into the infarcted area related to fibrosis.
Quantitative measurement of fibrosis area on cardiac sections showed a trend, but not reaching significance, towards the reduction of fibrosis in the scaffold group compared to EC group (12±1% versus 16±3%, respectively) (Fig. 5B ).
We also measured the local production of MMP-2 and MMP-9 using qRT-PCR. MMP-2 and MMP-9 mRNA per milligram of infarcted hearts were similar 1 and 2 months following MSC administration, whatever the delivery condition (not shown). In contrast, VEGF mRNA level was significantly higher 2 months after administration in the scaffold group (Fig. 5C, bottom row; p<0.05).
Echocardiographic and catheterism studies
Functional assessment by echocardiography was performed 7 days and 2 months after myocardial infarction and cardiac graft implantation. At the baseline (7th post-operative day) LVEDD, LVESD, and LVFS were similar in both EC (respectively 7.0±1; 5.5±1; 21.8±6.7; n=9) and scaffold groups (respectively 7.4±1.8; 5.4±1.8; 27±9.2; n=9) as in the control group having received non cellularized scaffolds (respectively 7.3±1.2; 5.2±1.4; 30.5±9.9; n=9). Progressive left ventricular dilatation and deterioration of LVFS were observed in the control group at 2 months. On the contrary, there was a trend towards a higher LVFS and a lower LVESD in the cellularized scaffold group at 2 months (Fig. 6 ).
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DISCUSSION
The approach to administer stem cells for cell therapy is mainly dependent of our ability to safely ensure sufficient delivery of cells within the target tissue and adequate local engraftment and function at this site. Different delivery strategies are required with regard to delivered cell types. For cardiac tissue, the intramyocardial route is suited to large, adherent cells and has been safely used for MSC infusion but suffers of a low engraftment rate. The potential interest of scaffolds in cardiac cell therapy is increasingly investigated to repair damaged tissue. 14, 15 The use of cells in combination with appropriate scaffold should provide not only a physical support for cell orientation and proliferation but also molecular cues to direct cell survival, cell cycle progression, and the expression of different phenotypes. 16 In this context, cell-seeded biocompatible cardiac patches could be considered as a promising approach. This study was designed to evaluate quantitatively MSC delivery in ischemic myocardium using a 3D scaffold in comparison with endocardial injection. Using a novel chemical cross-linking process combined with a porogen agent, polysaccharide-based porous scaffolds were prepared. MSCs were seeded into this porous scaffold that supports rapid integration of seeded cells.
The hydrogel structure would allow exchange of oxygen, nutrients, and metabolites inside the porous scaffold, as well as the diffusion of cells. We found that homing of MSCs from the scaffold to myocardium required a signal such as infarct remodelling. After 30 days, cell delivery was associated with a greater number of engrafted cells when compared to EC delivery, with about 10% of the initial seeded cells present in the scaffold group, in comparison with 5% following EC administration. This concurred with the MSC engraftment rate previously reported by Freyman et al after EC delivery in a porcine myocardial infarction model. 4 Differents factors could contribute to the improvement of cell delivery after implantation using a porous scaffold. A scaffold would provide a cell-friendly microenvironment as well as a substrate for the transplanted cells that would prevent cell loss. 17 It could also act as a mechanical support to enhance cell survival and cell proliferation. Indeed we observed an increase in GFP+ cell number from 1 month to 2 months after implantation, although this increase was not statistically significant. This suggests that a slight proliferation of implanted MSCs occurred.
Even if the mechanism of cardiovascular repair from adult stem cells remains highly unknown, it is believed that MSCs act through paracrine actions. In agreement, a significant, despite 14 modest, difference in the mRNA level of VEGF between scaffold and EC group was achieved here at 2 months, although no improved vascularization was evidenced (data not shown). We are also conducting a dose-effect study with GFP + cells to evaluate the relative contribution of cell engraftment to functional recovery. At the moment, limited functional data with GFP labelled cells suggested that a residual number of 3x10 5 MSC could sustained a regenerative effect.
Quantitative analysis of engrafted cells was performed using GFP
PTFE membrane could be also involved in the lack of significant benefit in terms of functional improvement in animal receiving cellularized scaffold maintained using this membrane.
Significant foreign body reaction and undesirable fibrous membrane with fibroblast proliferation has been reported using PTFE membrane; 22, 23 we observed by ourselves that membrane alone altered the epicardial anatomy. Control groups did not include the use of the PTFE membrane. At the time of the study, the membrane was the more convenient system to maintain our scaffold on the myocardial injury but we are now considering others devices.
Another approach is to construct 3D functional tissues by layering 2D cell sheets. 24, 25 This system allows for cell interconnection with gap junctions, resulting in electrically synchronous beating. Hamdi et al. recently compared such a bilayer myoblast cell sheet and a myoblast seeded collagen sponge. 26 In both cases, significant improvements in left ventricular ejection fraction (LVEF) compared with the controls were reported but could not be related to the detectable persistence of the myoblasts at the studied time point neither to an increased cytokine production. Residual cells were more abundant in the patch-treated hearts than in those covered with the myoblast sheets and the authors suggested that the benefits of cell transplantation could be potentiated by an epicardial deposition of a pre-shaped cellularized patch. In their study, the number of MSC at the time of delivery was not assessed since myoblast sheets production required 7 days of culture. 26 In another study, cells were embedded into a type I collagen matrix secured to heart with a fibrin sealant then cultured for 7 days. Despite high initial engraftment rates at 1 week, no hMSCs or residual patches were detectable at 4 weeks. 27 Addition of bioactive factors could modify the scaffold to specifically recruit stem cells in the cardiac injury site. 28 An injectable matrix metalloproteinase (MMP)-responsive, bioactive hydrogel was recently described as an in situ forming scaffold to deliver vascular cells derived from human embryonic stem cells (hESC). 29 Tissue-engineered cardiac grafts were also prepared by using various biomaterials such as small intestine submucosa (SIS) 30 and biodegradable porous alginate scaffolds, cultured for 4 to 7 days before implantation. 31 However, insufficient cell migration into scaffolds and inflammatory reaction due to scaffold biodegradation were reported. In comparison, our approach did not require any delay between seeding and implantation. Indeed, a fast infiltration of cells within the porous scaffold led to a cellularized patch 16 that could be implanted rapidly and seeded cells were thus evidenced here 1 and 2 months after scaffold implantation. A complete degradation of the scaffold was observed following implantation on infarcted tissue, but not on normal cardiac tissue. We have preliminary evidence of scaffolds degraded in vitro by leukocyte hydrolytic enzymes such as acid and alkaline phosphatase, as well as lysozyme, activities (unpublished results). Acid phosphatase and lysozyme have been shown to be more active in patients with acute myocardial infarction and might contribute to the in vivo degradation of scaffolds. 32 This complete degradation of the scaffold that was observed within a month might have promoted the local engraftment and survival of the cells.
In conclusion, we showed the feasibility to deliver MSCs to injured rat myocardium using a polysaccharide porous scaffold that improved engraftment in comparison with the most currently used approach of EC injection. Refinements of this approach, such as using injectable porous scaffolds containing appropriate molecules for cell differentiation or maintenance and sustained degradation profile may serve to enhance any benefits gained by cellular cardiomyoplasty. 
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